The company presented data on its orphan-designated lead asset to the European Association for Cancer Research Meeting ...

Immunovant is developing IMVT-1402 in an ongoing mid-stage study in Sjögren’s disease, which works the same way as Argenx’s ...

Cross-sectional data document the proliferation of potent synthetic opioids known as orphine analogues in the US drug supply, with a sharp increase since late 2025.

ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable targetCancer Research UK to fully ...

Judge Lewis J. Liman dismissed with prejudice an antitrust class-action lawsuit regarding the heart failure drug Entresto. The suit alleged ...

Eli Lilly first linked up with Gate Bioscience in July 2025 to leverage the biotech’s “Molecular Gate” engine to treat diseases with high unmet need. Monday’s expansion will add one undisclosed target ...

Ryan Brown seemed to have everything going for him – he survived two open-heart surgeries, worked as a senior systems ...

NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ARS Pharmaceuticals Inc. (""ARS Pharmaceuticals" or the ...

Detailed price information for Sino Biopharm Ord (SBMFF) from The Globe and Mail including charting and trades.

SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit ...

A two-day police operation targeting drug offences in and around Chorley town centre has led to two arrests and the seizure ...

ORIC-259 is a potential first-in-class small molecule mRNA degrader targeting CIP2A, a previously undruggable target Cancer Research UK to fully fund, sponsor, design, and execute CTA-enabling studies ...